Sponsor Overview
Explore verified public information about Matrix Biomed, Inc.'s expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 2 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 1 supporting sources.
“Matrix Biomed, Inc. will consider compassionate use of one of our investigational drugs if all of the following are met: - The patient has a life-threatening or severely debilitating disease with no comparable or satisfactory alternative therapies; - The patient is ineligible for, or otherwise unable to, participate in a clinical trial; - The patient has a disease for which there is sufficient evidence to project a benefit from the use of the investigational drug ; - The investigational drug is currently in clinical development and being tested on humans; and - Providing the investigational drug under compassionate use does not interfere with the initiation, conduct, or completion of clinical trials.”
Active EAPs on ClinicalTrials.gov
Score contribution: 60 — 2 supporting sources.
Conditions: Prostate Cancer
Conditions: Metastatic Cancer
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.